Quanterix Corporation
Financials
Valuation Metrics
Quanterix Corporation's Market Cap is $132M. At end of 2025 it was $298M. Ranked #3034 of 3,118 in US market (top 97%), #1401 of 1,474 on NASDAQ (top 95%), #194 of 203 in Health Care Equipment & Services (top 96%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $132M | US#3,034/3,118 Sec#194/203 |
| Revenue | $153M | US#2,599/3,118 Sec#174/203 |
| Net Income | $-123M | US—/3,118 Sec—/203 |
| Total Assets | $320M | US#2,893/3,118 Sec#177/203 |
| Net Assets | $237M | US#2,608/3,118 Sec#155/203 |
| Employees | 450 | US#2,299/3,118 Sec#159/203 |
| Value | ||
| P/B | 0.56x | US#123/3,118 Sec#9/203 |
| P/S | 0.86x | US#644/3,118 Sec#42/203 |
| FCF Yield | -56.09% | US—/3,118 Sec—/203 |
| Profitability | ||
| ROE | -51.90% | US#2,680/3,118 Sec#170/203 |
| ROA | -38.52% | US#2,933/3,118 Sec#193/203 |
| Op. Margin | -86.19% | US#2,695/3,118 Sec#192/203 |
| Revenue Growth | 23.41% | US#574/3,118 Sec#36/203 |
| Financial Health | ||
| Debt Ratio | 34.74% | US#395/3,118 Sec#40/203 |
| Total Debt | $33M | US#2,668/3,118 Sec#162/203 |
| FCF | $-74M | US#2,581/3,118 Sec#184/203 |
| Cash | $44M | US#2,621/3,118 Sec#170/203 |
| Current Ratio | 3.40x | US#664/3,118 Sec#66/203 |
| Performance | ||
| 1Y Return | -47.57% | US#2,767/3,118 Sec#175/203 |
| 1M Return | -23.08% | US#2,844/3,118 Sec#192/203 |
| From 52W High | -68.07% | US#2,935/3,118 Sec#196/203 |
| 1Y MDD | -69.98% | US#2,927/3,118 Sec#188/203 |
| Trading | ||
| Volume | 467,089 shares | US#2,361/3,118 Sec#169/203 |
| Trading Value | $1M | US#3,013/3,118 Sec#192/203 |
| Per Share | ||
| EPS | $-2.61 | US—/3,118 Sec—/203 |
| BPS | $5.04 | US#2,270/3,118 Sec#142/203 |
Company Info
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.